DSGN
DSGN clinical trials: Design Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Design Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 5
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
DSGN on the catalyst calendar · DSGN registry changes
- Primary completion Dec 2027Sponsor estimatePhase 2NCT07024693DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyDesign Therapeutics, Inc. · Fuchs Endothelial Corneal DystrophyRecruitingDSGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06874010A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's AtaxiaDesign Therapeutics, Inc. · Friedreich AtaxiaRecruitingDSGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2025Sponsor estimatePhase 1NCT06772870A Single Ascending Dose Study of DT-216P2 in Normal Healthy ParticipantsDesign Therapeutics, Inc. · Friedreich AtaxiaNot yet recruitingDSGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2023ActualPhase 1NCT05573698Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich AtaxiaDesign Therapeutics, Inc. · Friedreich AtaxiaCompletedDSGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2022ActualPhase 1NCT05285540Study to Evaluate DT-216 in Adult Patients With Friedreich AtaxiaDesign Therapeutics, Inc. · Friedreich AtaxiaCompletedDSGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner